DE122008000051I1 - 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel - Google Patents
2-arylthiazolderivat sowie dieses enthaltendes arzneimittelInfo
- Publication number
- DE122008000051I1 DE122008000051I1 DE122008000051C DE122008000051C DE122008000051I1 DE 122008000051 I1 DE122008000051 I1 DE 122008000051I1 DE 122008000051 C DE122008000051 C DE 122008000051C DE 122008000051 C DE122008000051 C DE 122008000051C DE 122008000051 I1 DE122008000051 I1 DE 122008000051I1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- arylthiazol
- derivative
- optionally protected
- represents hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Residential Or Office Buildings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33014790 | 1990-11-30 | ||
JP21658691 | 1991-08-02 | ||
PCT/JP1991/001670 WO1992009279A1 (en) | 1990-11-30 | 1991-11-29 | 2-arylthiazole derivative and pharmaceutical composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DE122008000051I1 true DE122008000051I1 (de) | 2009-02-05 |
Family
ID=26521514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE122008000051C Pending DE122008000051I1 (de) | 1990-11-30 | 1991-11-29 | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
DE69122084T Expired - Lifetime DE69122084T2 (de) | 1990-11-30 | 1991-11-29 | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69122084T Expired - Lifetime DE69122084T2 (de) | 1990-11-30 | 1991-11-29 | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
Country Status (13)
Country | Link |
---|---|
US (1) | US5614520A (de) |
EP (1) | EP0513379B1 (de) |
JP (1) | JP2725886B2 (de) |
KR (1) | KR100221041B1 (de) |
AT (1) | ATE142494T1 (de) |
AU (1) | AU645867B2 (de) |
CA (1) | CA2073981C (de) |
DE (2) | DE122008000051I1 (de) |
DK (1) | DK0513379T3 (de) |
ES (1) | ES2092580T3 (de) |
HU (1) | HU218942B (de) |
SG (1) | SG86971A1 (de) |
WO (1) | WO1992009279A1 (de) |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294630A (en) * | 1992-07-07 | 1994-03-15 | Eli Lilly And Company | Treatment of inflammatory bowel disease |
US5436258A (en) * | 1992-09-09 | 1995-07-25 | Eli Lilly And Company | Prevention of bone resorption |
EP0695742A1 (de) | 1994-08-03 | 1996-02-07 | Hoechst Aktiengesellschaft | Fullerenazirin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung |
ES2224160T3 (es) * | 1995-04-07 | 2005-03-01 | Teijin Limited | Agente protector para organo o tejido. |
KR970061878A (ko) * | 1996-02-23 | 1997-09-12 | 성재갑 | 신규한 아릴티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 하는 제초제 조성물 |
IL129748A (en) | 1996-10-07 | 2003-11-23 | Lilly Co Eli | Phenyl oxazole, thiazole, oxazoline, oxadiazole and benzoxazole compounds and neuro-protective pharmaceutical compositions comprising the same |
US6472387B1 (en) | 1996-10-07 | 2002-10-29 | Eli Lilly And Company | Methods of using compounds as neuro-protective agents |
ID21775A (id) * | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
AU9575698A (en) | 1997-10-06 | 1999-04-27 | Eli Lilly And Company | Novel compounds useful as neuro-protective agents |
PL200710B1 (pl) * | 1998-06-19 | 2009-01-30 | Teijin Pharma Ltd | Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania |
US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
NZ509172A (en) | 1998-09-21 | 2004-02-27 | Univ Florida | Antimalarial agents |
US6410562B1 (en) | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
US6528652B1 (en) * | 1999-01-21 | 2003-03-04 | Chronimed | Composition and device for detecting leukocytes in urine |
US6348324B1 (en) | 1999-01-21 | 2002-02-19 | Hypoguard America Limited | Composition and device for detecting leukocytes in urine |
EP2241328A1 (de) * | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen |
DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
WO2002094798A1 (fr) * | 2001-05-23 | 2002-11-28 | Nippon Soda Co.,Ltd. | Preparation de composes thiazole |
KR100981905B1 (ko) * | 2002-03-28 | 2010-09-13 | 데이진 화-마 가부시키가이샤 | 단일 결정형을 함유하는 고형제제 |
US6933308B2 (en) * | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
US7273866B2 (en) * | 2002-12-20 | 2007-09-25 | Bristol-Myers Squibb Company | 2-aryl thiazole derivatives as KCNQ modulators |
US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
US7208514B2 (en) | 2003-03-13 | 2007-04-24 | Mitsubishi Pharma Corporation | Tumorigenesis inhibitor |
US20050027128A1 (en) * | 2003-07-30 | 2005-02-03 | Robbins Timothy A. | Substituted thiazoles |
WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
US7037927B2 (en) * | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7485657B2 (en) * | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
JP4914210B2 (ja) * | 2004-06-14 | 2012-04-11 | 日本ケミファ株式会社 | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 |
WO2006022375A1 (ja) * | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | 2-フェニルチオフェン誘導体 |
KR20070045272A (ko) | 2004-08-27 | 2007-05-02 | 아스텔라스세이야쿠 가부시키가이샤 | 2-페닐피리딘 유도체 |
EP2363129A1 (de) * | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Verbindungen zur Nonsense-Unterdrückung und Verfahren zu deren Verwendung |
US7790720B2 (en) * | 2005-03-31 | 2010-09-07 | Ucb Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
DK1866296T3 (en) | 2005-04-04 | 2017-02-13 | Univ Florida | DESFERRITHIOCINPOLYETHER-ANALOGS |
EP1883405A4 (de) | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | Verfahren zur behandlung von nephrolithiase |
JP2009501721A (ja) * | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
CA2617248C (en) * | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
JP5222561B2 (ja) * | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
US7816558B2 (en) * | 2005-10-07 | 2010-10-19 | Astellas Pharma Inc. | Triarylcarboxylic acid derivative |
CN1954814A (zh) * | 2005-10-26 | 2007-05-02 | 重庆医药工业研究院有限责任公司 | 一种具有协同作用治疗痛风的药物组合物及其制备方法 |
CN100430055C (zh) * | 2005-11-11 | 2008-11-05 | 天津泰普药品科技发展有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
WO2007097403A1 (ja) | 2006-02-24 | 2007-08-30 | Astellas Pharma Inc. | 消化管潰瘍治療又は予防薬 |
JP4999923B2 (ja) * | 2006-06-13 | 2012-08-15 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物 |
US8318792B2 (en) | 2006-07-19 | 2012-11-27 | Nippon Medical School Foundation | Therapeutic agent for amyotrophic lateral sclerosis |
CN101139325B (zh) * | 2006-09-07 | 2010-05-12 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
CN101812035B (zh) * | 2006-09-07 | 2012-03-21 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
WO2008064015A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
CN1970547B (zh) * | 2006-12-07 | 2011-04-06 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
CN102093308B (zh) * | 2006-12-07 | 2012-08-29 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
CN102093309B (zh) * | 2006-12-07 | 2012-07-04 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
MX2009007680A (es) * | 2007-01-19 | 2011-08-03 | Takeda Pharmaceuticals North America Inc | Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios. |
BRPI0809077A2 (pt) | 2007-03-15 | 2014-09-09 | Univ Florida Res Foudantion Inc | Análogos de poliéter de desferritiocina |
WO2008126772A1 (ja) * | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | 高血圧治療剤 |
BR122018001851B1 (pt) | 2007-08-13 | 2019-08-20 | Monsanto Technology Llc | Método de controle de nematódeos parasitas de plantas |
CA2739060C (en) * | 2008-10-15 | 2016-08-23 | Kissei Pharmaceutical Co., Ltd. | Fused-ring derivative and medical application of same |
WO2010044410A1 (ja) * | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | ビアリールイソニコチン酸誘導体及びその医薬用途 |
CN101759656B (zh) * | 2008-12-12 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 非布司他新晶型及其制备方法 |
CN101768150B (zh) * | 2009-01-05 | 2014-08-06 | 常州市第四制药厂有限公司 | 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法 |
CN101781270B (zh) * | 2009-01-20 | 2013-03-27 | 重庆医药工业研究院有限责任公司 | 一种高纯度的非布司他及其制备方法 |
US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
CN101475541B (zh) * | 2009-02-09 | 2011-05-25 | 扬州哈泰克材料有限公司 | 4-甲基噻唑-5-羧酸的一种制备方法 |
ES2459722T3 (es) | 2009-02-27 | 2014-05-12 | Teijin Pharma Limited | Procedimiento para producir un derivado heterocíclico sustituido con fenilo mediante acoplamiento usando un catalizador de metal de transición |
CN101580495A (zh) * | 2009-05-25 | 2009-11-18 | 沈阳药科大学 | 5-取代苯基-3-异噁唑甲酸及其酯类化合物、组合物及其制备方法 |
JP5336593B2 (ja) | 2009-06-09 | 2013-11-06 | 帝人ファーマ株式会社 | 4−置換ベンゾチオアミド誘導体の製造法 |
PT2398784E (pt) | 2009-06-10 | 2012-12-27 | Teva Pharma | Formas cristalinas do febuxostat |
EP2266966A1 (de) * | 2009-06-11 | 2010-12-29 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Febuxostat |
CN101928259B (zh) * | 2009-06-18 | 2012-10-03 | 南京海辰药业有限公司 | 2-芳基噻唑衍生物及其药物组合物 |
BRPI1011456A2 (pt) | 2009-06-26 | 2016-03-15 | Teijin Pharma Ltd | droga terapeutica ou uma droga preventiva e metodo terapeutico ou um metodo preventivo para hipertensao ou pressao arterial alta-normal |
CN103936689B (zh) * | 2009-07-17 | 2016-08-17 | 北京利乐生制药科技有限公司 | 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法 |
WO2011031409A1 (en) | 2009-09-10 | 2011-03-17 | Teva Pharmaceutical Industries Ltd. | Processes for preparing febuxostat |
IT1395936B1 (it) * | 2009-09-29 | 2012-11-02 | Dipharma Francis Srl | Sali di febuxostat |
TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
WO2011073617A1 (en) | 2009-12-14 | 2011-06-23 | Cipla Limited | Processes for the preparation of febuxostat and salts thereof |
WO2011080651A2 (en) | 2009-12-31 | 2011-07-07 | Ranbaxy Laboratories Limited | Polymorphic forms of febuxostat |
EP2536699A2 (de) | 2010-02-19 | 2012-12-26 | Cadila Healthcare Limited | Substanziell reine salze aus febuxostat und verfahren zur herstellung davon |
WO2011103439A1 (en) * | 2010-02-19 | 2011-08-25 | Takeda Pharmaceuticals North America, Inc. | Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors |
EP2542540A1 (de) | 2010-03-04 | 2013-01-09 | Ranbaxy Laboratories Limited | Polymorph aus 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazol-5-carbonsäure |
EP2563768A4 (de) | 2010-04-29 | 2013-07-31 | Reddys Lab Ltd Dr | Herstellung von febuxostat |
IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
IT1400310B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e statine e loro uso. |
IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
EP2582664A4 (de) | 2010-06-16 | 2014-07-09 | Ardea Biosciences Inc | Phenylthioacetatverbindungen und -zusammensetzungen sowie verfahren zu ihrer verwendung |
EP2582812B1 (de) | 2010-06-16 | 2018-01-24 | Takeda Pharmaceuticals U.S.A., Inc. | Neue dosierungsformen modifizierter freisetzung von xanthin-oxidoreduktase-hemmern oder xanthin-oxidase-hemmern |
AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
SG186798A1 (en) | 2010-06-25 | 2013-02-28 | Teijin Pharma Ltd | Sustained-release therapeutic agent for hypertension and renal dysfunction |
AR081267A1 (es) * | 2010-07-13 | 2012-07-18 | Interquim Sa | Procedimiento de obtencion de la forma cristalina a del febuxostat |
WO2012014117A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Improved process for the preparation of febuxostat |
WO2012020272A2 (en) | 2010-08-13 | 2012-02-16 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New salts, polymorphs and solvates of a pharmaceutical active ingredient |
ES2589977T3 (es) | 2010-08-27 | 2016-11-17 | Teijin Pharma Limited | Método para la producción de derivados heterocíclicos sustituidos con fenilos mediante medios de método de acoplamiento utilizando un compuesto de palladio |
WO2012032528A2 (en) | 2010-09-08 | 2012-03-15 | Natco Pharma Limited | Improved process to prepare ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate |
AU2011299153B2 (en) | 2010-09-10 | 2014-10-30 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
US20130303780A1 (en) | 2010-11-08 | 2013-11-14 | Siva Rama Prasad Vellanki | Process for the preparation of 2-arylthiazole derivatives |
WO2012073259A1 (en) | 2010-12-02 | 2012-06-07 | Indoco Remedies Limited | Novel process for the preparation of febuxostat |
WO2012098501A1 (en) | 2011-01-21 | 2012-07-26 | Ranbaxy Laboratories Limited | Febuxostat co-crystals |
WO2012109573A1 (en) * | 2011-02-11 | 2012-08-16 | Purdue Research Foundation | Substituted thiazoles for use as antiviral agents |
CN102643249A (zh) * | 2011-02-18 | 2012-08-22 | 苏州波锐生物医药科技有限公司 | 2-芳基噻唑衍生物,其可药用盐及用途 |
WO2012131590A1 (en) | 2011-03-31 | 2012-10-04 | Sandoz Ag | An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof |
WO2012140632A1 (en) | 2011-04-15 | 2012-10-18 | Ranbaxy Laboratories Limited | Febuxostat solid dispersion |
WO2012153313A1 (en) | 2011-05-11 | 2012-11-15 | Ranbaxy Laboratories Limited | Pharmaceutical composition of febuxostat |
WO2012172461A1 (en) | 2011-06-13 | 2012-12-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of febuxostat |
US20140228417A1 (en) * | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
TW201328692A (zh) * | 2011-10-11 | 2013-07-16 | Univ Osaka | 脫髓鞘疾病之治療劑及預防劑 |
CA2852490A1 (en) | 2011-11-03 | 2013-05-10 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound to reduce serum uric acid levels |
JP2014533297A (ja) * | 2011-11-15 | 2014-12-11 | マイラン ラボラトリーズ リミテッドMylan Laboratories Limited | フェブキソスタットの多形の調製方法 |
WO2013088449A1 (en) | 2011-12-16 | 2013-06-20 | Natco Pharma Limited | Stable crystal form of febuxostat and process for the preparation thereof |
US20140343110A1 (en) | 2011-12-16 | 2014-11-20 | University Of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
SI2793883T1 (en) * | 2011-12-19 | 2018-08-31 | Dompe Farmaceutici S.P.A. | Antagonists TRPM8 |
EP2606888A1 (de) * | 2011-12-19 | 2013-06-26 | Dompe' S.P.A. | TRPM8-Antagonisten |
JP5924699B2 (ja) * | 2012-01-27 | 2016-05-25 | 帝人ファーマ株式会社 | 糖尿病の治療薬 |
WO2014009817A1 (en) | 2012-07-12 | 2014-01-16 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of febuxostat |
EP2692342A1 (de) | 2012-07-30 | 2014-02-05 | Interquim, S.A. | Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Febuxostat in Tablettenform |
CN103130744B (zh) * | 2012-08-28 | 2014-10-15 | 沈阳药科大学 | 一种硒唑甲酸类化合物及其制备方法和用途 |
WO2014057461A1 (en) | 2012-10-11 | 2014-04-17 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form g of febuxostat |
WO2014065275A1 (ja) * | 2012-10-23 | 2014-05-01 | 国立大学法人福井大学 | 腫瘍融解症候群の治療薬及び予防薬 |
CN103848798B (zh) * | 2012-11-30 | 2016-01-06 | 镇江新元素医药科技有限公司 | 2-芳基硒唑化合物及其药物组合物 |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
CN103936693B (zh) * | 2013-01-22 | 2016-06-15 | 沈阳药科大学 | 2-(3-氰基-4-取代苯基)-4-甲基-1,3-硒唑-5-甲酸及其酯类化合物和制备方法 |
TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
CN103333134B (zh) * | 2013-03-01 | 2016-02-24 | 沈阳药科大学 | 2-(3-氰基-4-烷氧基)苯基-4-取代噻唑-5-甲酸类化合物、组合物及其制备方法和用途 |
CN104163782A (zh) * | 2013-05-17 | 2014-11-26 | 重庆圣华曦药业股份有限公司 | 一种制备3,4-取代的硫代苯甲酰胺的方法及其在非布司他合成中的应用 |
WO2014192977A1 (ja) * | 2013-05-31 | 2014-12-04 | 帝人ファーマ株式会社 | チアゾール誘導体 |
WO2015018507A2 (en) | 2013-08-07 | 2015-02-12 | Pharmathen S.A. | A novel process for the preparation of febuxostat |
CN104418822B (zh) * | 2013-08-22 | 2016-12-28 | 南京华威医药科技开发有限公司 | 具有黄嘌呤氧化酶抑制活性的化合物及其用途 |
CN103524456B (zh) * | 2013-09-30 | 2016-06-01 | 南京华威医药科技开发有限公司 | 一种硒唑甲酸类化合物及其盐 |
EP3071201A4 (de) | 2013-11-22 | 2017-04-26 | University of Florida Research Foundation, Inc. | Desferrithiocin-analoga und verwendungen davon |
EP2881116A1 (de) | 2013-12-05 | 2015-06-10 | Ranbaxy Laboratories Limited | Febuxostatzusammensetzung |
AU2015260294A1 (en) * | 2014-05-13 | 2017-01-05 | Teijin Pharma Limited | Novel crystalline polymorph of pyridine derivative, and method for producing same |
US10196368B2 (en) * | 2014-06-23 | 2019-02-05 | Dompé Farmaceutici S.P.A. | 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma |
US20170217948A1 (en) * | 2014-07-30 | 2017-08-03 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
BR112017001657B1 (pt) * | 2014-07-30 | 2023-01-17 | Teijin Pharma Limited | Cristal, composto, composição farmacêutica, inibidor de xantina oxidase, agente terapêutico ou profilático para uma ou mais doenças, e, método de produção da forma de um cristal. |
JP2017165653A (ja) * | 2014-07-30 | 2017-09-21 | 帝人ファーマ株式会社 | アゾールカルボン酸誘導体 |
TR201818775T4 (tr) | 2014-07-30 | 2019-01-21 | Teijin Pharma Ltd | Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali. |
CZ27857U1 (cs) | 2014-12-12 | 2015-02-23 | Zentiva, K.S. | Formulace obsahující tuhý roztok febuxostatu |
CN107427517B (zh) | 2015-02-24 | 2021-11-16 | 国立大学法人鸟取大学 | 用于痴呆症的预防及/或治疗的医药 |
US9809586B2 (en) | 2015-03-28 | 2017-11-07 | Wisconsin Alumni Research Foundation | Inhibitors of collagen prolyl 4-hydroxylase |
CA2984250A1 (en) | 2015-04-27 | 2016-11-03 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
EP3344604B1 (de) * | 2015-09-02 | 2020-11-04 | Sunshine Lake Pharma Co., Ltd. | Carboxy-substituierte (hetero) aromatische ringderivate und herstellungsverfahren und verwendungen davon |
JP6732004B2 (ja) | 2016-02-19 | 2020-07-29 | 国立大学法人鳥取大学 | 認知症治療薬または予防薬 |
CN106146419A (zh) * | 2016-08-01 | 2016-11-23 | 沈阳药科大学 | 黄嘌呤氧化酶抑制剂 |
CN108358866B (zh) * | 2017-01-12 | 2021-03-23 | 江西同和药业股份有限公司 | 一种非布司他中间体的制备方法及其在制备非布司他中的应用 |
CN110066258A (zh) * | 2018-01-23 | 2019-07-30 | 湘北威尔曼制药股份有限公司 | 噻唑-5-甲酸衍生物及其制备方法与应用 |
CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
CN109810073B (zh) * | 2019-02-28 | 2023-01-06 | 南京海辰药业股份有限公司 | 4-芳基噻唑衍生物及其药物组合物 |
CN114341120A (zh) | 2019-08-21 | 2022-04-12 | 国立大学法人东京大学 | Abcc11抑制剂 |
CN113024534B (zh) * | 2019-12-24 | 2023-03-21 | 武汉光谷亚太医药研究院有限公司 | 2-吡啶基噻唑衍生物及其应用 |
CN115572272B (zh) * | 2022-11-15 | 2024-05-07 | 湖北华世通生物医药科技有限公司 | 非布司他及其醛基酯类中间体的制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
CA962269A (en) * | 1971-05-05 | 1975-02-04 | Robert E. Grahame (Jr.) | Thiazoles, and their use as insecticides |
DE2125193C3 (de) * | 1971-05-21 | 1980-08-14 | Basf Ag, 6700 Ludwigshafen | 4-Nitro-2-thiazolyl-1 -aminobenzole und Verfahren zu ihrer Herstellung |
DE2125251A1 (en) * | 1971-05-21 | 1972-11-30 | Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen | Monoazo dispersion dyes - contg a thiazolyl substit in 2-position for use on synthetic fibres |
US3852293A (en) * | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
US4020080A (en) * | 1974-07-01 | 1977-04-26 | Eastman Kodak Company | Oxadiazolylphenyl aromatic ester compounds and their use as ultraviolet stabilizer in organic compositions |
US4363813A (en) * | 1979-07-09 | 1982-12-14 | Kureha Kagaku Kogyo Kabushiki Kaisha | 2-(3,4,5-Trimethoxyphenyl)-4,5-disubstituted thiazoles |
DE3002989A1 (de) * | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
US4346094A (en) * | 1980-09-22 | 1982-08-24 | Eli Lilly And Company | 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels |
JPS5772975A (en) * | 1980-10-24 | 1982-05-07 | Kureha Chem Ind Co Ltd | 2-substituted phenylthiazole derviative, and medicine for peptic ulcer containing said derivative as active component |
DE3141430A1 (de) * | 1981-10-19 | 1983-05-05 | Basf Ag, 6700 Ludwigshafen | Heterocyclisch substiutierte azofarbstoffe |
US4571402A (en) * | 1982-06-22 | 1986-02-18 | Schering Corporation | Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
US4528291A (en) * | 1982-06-22 | 1985-07-09 | Schering Corporation | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility |
JPS5925381A (ja) * | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | 新規なフエニル酢酸誘導体 |
JPH0725754B2 (ja) * | 1986-01-30 | 1995-03-22 | 富山化学工業株式会社 | 新規なチアゾール化合物またはその塩 |
JPH01110683A (ja) * | 1986-09-27 | 1989-04-27 | Sawai Seiyaku Kk | N−テトラゾリルチアゾールカルボキシアミド誘導体およびその用途 |
JPS63112572A (ja) * | 1986-10-30 | 1988-05-17 | Yamanouchi Pharmaceut Co Ltd | 2(3h)−チアゾロン誘導体 |
JPS63112574A (ja) * | 1986-10-30 | 1988-05-17 | Yamanouchi Pharmaceut Co Ltd | 4−トリ置換フエニル−2(3h)−チアゾロン誘導体 |
EP0457803A4 (en) * | 1989-02-08 | 1991-12-04 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
JPH02229190A (ja) * | 1989-03-02 | 1990-09-11 | Taisho Pharmaceut Co Ltd | アゾール誘導体 |
US5244867A (en) * | 1989-09-26 | 1993-09-14 | Basf Aktiengesellschaft | Oxazole- and thiazolecarboxamides |
-
1991
- 1991-11-29 CA CA002073981A patent/CA2073981C/en not_active Expired - Lifetime
- 1991-11-29 ES ES91920699T patent/ES2092580T3/es not_active Expired - Lifetime
- 1991-11-29 SG SG9603299A patent/SG86971A1/en unknown
- 1991-11-29 HU HU9202265A patent/HU218942B/hu unknown
- 1991-11-29 EP EP91920699A patent/EP0513379B1/de not_active Expired - Lifetime
- 1991-11-29 DE DE122008000051C patent/DE122008000051I1/de active Pending
- 1991-11-29 KR KR1019920701809A patent/KR100221041B1/ko not_active IP Right Cessation
- 1991-11-29 AT AT91920699T patent/ATE142494T1/de not_active IP Right Cessation
- 1991-11-29 JP JP4500083A patent/JP2725886B2/ja not_active Expired - Lifetime
- 1991-11-29 WO PCT/JP1991/001670 patent/WO1992009279A1/ja active IP Right Grant
- 1991-11-29 AU AU89522/91A patent/AU645867B2/en not_active Expired
- 1991-11-29 DK DK91920699.5T patent/DK0513379T3/da active
- 1991-11-29 DE DE69122084T patent/DE69122084T2/de not_active Expired - Lifetime
-
1995
- 1995-01-30 US US08/380,214 patent/US5614520A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2092580T3 (es) | 1996-12-01 |
US5614520A (en) | 1997-03-25 |
CA2073981A1 (en) | 1992-05-31 |
HU9202265D0 (en) | 1992-10-28 |
EP0513379A1 (de) | 1992-11-19 |
CA2073981C (en) | 2002-01-08 |
KR927003052A (ko) | 1992-12-17 |
HUT63838A (en) | 1993-10-28 |
SG86971A1 (en) | 2002-03-19 |
EP0513379B1 (de) | 1996-09-11 |
AU8952291A (en) | 1992-06-25 |
HU218942B (hu) | 2001-01-29 |
WO1992009279A1 (en) | 1992-06-11 |
ATE142494T1 (de) | 1996-09-15 |
DE69122084D1 (de) | 1996-10-17 |
KR100221041B1 (ko) | 1999-09-15 |
DE69122084T2 (de) | 1997-04-03 |
JP2725886B2 (ja) | 1998-03-11 |
EP0513379A4 (en) | 1993-09-01 |
DK0513379T3 (da) | 1996-09-30 |
AU645867B2 (en) | 1994-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE122008000051I1 (de) | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel | |
DK0736018T3 (da) | 4,5-Diaryloxazolderivater | |
IL103564A0 (en) | Aromatic amidine derivatives and pharmaceutical compositions containing them | |
DE69016667D1 (de) | Stabilisierte komplexe bestehend aus stickoxyd/primäre amine zur verwendung als kardiovaskuläre wirkstoffe. | |
DE69528005D1 (de) | Prolineamid-Derivate | |
ATE226574T1 (de) | 4,6-diarylpyrimidin-derivate und deren salze | |
HUP0001269A2 (hu) | 2-Oxo-1-azetidin-szulfonsav-származékok és ezeket tartalmazó kombinált gyógyszerkészítmények | |
NO306992B1 (no) | Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene | |
NO923126D0 (no) | Preparat og metode for behandling av canser | |
NO923200D0 (no) | Piperidin-derivater | |
HU9300202D0 (en) | Benzo-pyrane derivatives, pharmaceutical preparatives containing them as active substance as well as method for producing them | |
NO20020804D0 (no) | Nye A-500359-derivater | |
DE69300318D1 (de) | Flavonderivate. | |
DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
ES2098070T3 (es) | Derivados de piperidina con una actividad antihistaminica y antileucotrienica. | |
EP0601181A4 (en) | Benzofuran derivative and pharmaceutical composition. |